Target intelligence / Profile preview

Atypical chemokine receptor 5 (ACKR5)

Target
ACKR5
Molecular classification
G protein-coupled receptor, Chemokine receptor, Atypical chemokine receptor, Rhodopsin-like GPCR
01

Overview

Atypical chemokine receptor 5 (ACKR5), commonly known as G protein-coupled receptor 182 (GPR182), is a member of the atypical chemokine receptor family within the larger GPCR superfamily. Unlike canonical chemokine receptors, it does not transmit classical G-protein-dependent intracellular signals upon ligand binding, but instead serves as a scavenger receptor for multiple chemokines, including CXCL10, CXCL12, CXCL13, and CCL28[1][2]. ACKR5 is broadly expressed in endothelial cells of blood and lymphatic vasculature across various organs and has a central role in controlling chemokine levels in tissues and blood. The receptor regulates immune cell migration and tissue organization by shaping chemokine gradients, and its deficiency leads to dysregulated chemokine levels, hematopoietic stem cell egress from the bone marrow, and altered splenic architecture. As of the current literature, no drugs are approved to specifically modulate ACKR5/GPR182 activity[1][2].

Other names
G-protein coupled receptor 182GPR182adrenomedullin receptorAM-RADMRhrhAMRG10D7TMRL1-Rgamrh
02

Mechanism of action

Scavenging/binding of chemokines (e.g., CXCL10, CXCL12, CXCL13, CCL28) without inducing classical G-protein signaling; reduces local and systemic concentrations of these chemokines by internalization and degradation[1][2].

03

Biological functions

Chemokine scavengingRegulation of immune cell traffickingMaintenance of chemokine gradientsControl of hematopoietic stem cell homeostasisRegulation of splenic marginal zone architecture
04

Disease associations

InflammationImmune dysregulation (potential)Altered hematopoiesis (potential impact on bone marrow homeostasis)Potential roles in cancer (due to expression in tumor-associated lymphatics and altered splenic architecture)
05

Safety considerations

Disturbance of local chemokine homeostasis (potential for immune dysregulation)[1][2].Possible alteration in hematopoietic stem cell trafficking (noted in knockout models)[2].Potential effects on secondary lymphoid organ structure and immune response[1].
06

Biomarkers

Elevated serum levels of CXCL10, CXCL12, or CXCL13 in GPR182-deficient/ACKR5-deficient states[1][2].Reduced size and cellularity of splenic marginal zones in knockout models[1].

Beyond the preview

Go deeper on Atypical chemokine receptor 5 (ACKR5).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Atypical chemokine receptor 5 (ACKR5).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call